ImaginAb Competitors and Similar CompaniesClear all
Dr Lal PathLabs's competitors and similar companies include Mesoblast and ImmusanT.
 Dr Lal PathLabs Dr Lal PathLabs is an international service provider of diagnostic and related healthcare tests. |  Mesoblast Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. |  ImmusanT ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. | |
Founding Date | Founding Date 1949 | Founding Date 2004 | Founding Date 2010 |
Type | Type Public | Type Public | Type Private |
Tags | |||
Locations | Locations Gurugram, IN HQ | Locations Melbourne, AU HQ Singapore, SG New York, US | Locations Cambridge, US HQ |
Employees | Employees 4,099 | Employees 73 | Employees 2 |
Financial | |||
Revenue (est.) | Revenue (est.) ₹27.6b (FY, 2026) | Revenue (est.) $17.2m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods ₹5.3b (FY, 2026) | Cost of goods $1.2m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit ₹23.3b (FY, 2026) | Gross profit $16.1m (FY, 2025) | Gross profit N/A |
Net income | Net income ₹5.1b (FY, 2026) | Net income ($102.1m) (FY, 2025) | Net income N/A |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 56.2m | Total funding raised $ 72.8m |
For sources of this data, please see the company profile
View Company Profiles
Mesoblast
HQ
Melbourne, AU
Employees
73
Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine.
View companyImmusanT
HQ
Cambridge, US
Employees
2
ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases.
View company